Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

August 15, 2027

Study Completion Date

December 1, 2028

Conditions

Arthritis, Rheumatoid

Interventions

DRUG

Etanercept

50 mg subcutaneously weekly

DRUG

Adalimumab

40 mg subcutaneously every 2 weeks

DRUG

Upadacitinib

15 mg orally once daily with subcutaneous placebo injection every 2 weeks

DRUG

Tocilizumab

162 mg administered SQ every 2 weeks

Trial Locations (1)

Tufts Medical Center, Boston

All Listed Sponsors

lead

Tufts Medical Center

OTHER